Correction to: Significance of postoperative adjuvant chemotherapy with an oxaliplatin-based regimen after simultaneous curative resection for colorectal cancer and synchronous colorectal liver metastasis: a propensity score matching analysis

An amendment to this paper has been published and can be accessed via the original article.

Simultaneous Hepatectomy as a Safe Approach for Synchronous Colorectal Liver Metastasis

Objective: The optimal surgical strategy for treatment of colorectal cancer with synchronous liver metastasis remains controversial. This retrospective analysis compared both surgical and perioperative outcomes for patients receiving simultaneous hepatectomy and primary colorectal surgery, to those receiving hepatectomy alone for stage approach. Material and Methods: Between; June, 2013 and June, 2019, 111 patients underwent a hepatectomy for synchronous liver metastasis, from this 90 patients received stage resection (hepatectomy alone group), and 21 patients received simultaneous resection (simultaneous resection group) with primary colorectal cancer. Results:There were no significant differences in gender, age, primary tumor location, tumor size, number of liver metastasis, estimated blood loss, nor rate of blood transfusion. However, the hepatectomy alone group was significantly higher in the proportion of preoperative chemotherapy, compared to the simultaneous resection group (93.3 vs. 38.1%, respectively; p-value<0.001). Additionally, total operative time in the simultaneous resection group was significantly longer, when compared to the hepatectomy alone group (530 vs. 300 minutes, respectively; p-value<0.001). The length of hospital stay was also longer in the simultaneous resection group, compared to the hepatectomy alone group (10 days vs. 7 days, respectively; p-value<0.001). However, the rate of major postoperative complications were similar (14.3 vs. 10.0%; p value=0.525), respectively. Additionally, major hepatectomy and simultaneous resection were not significantly associated with any major complications. Conclusion: Simultaneous hepatectomy in synchronous colorectal liver metastasis is a safe approach, and does not increase the risks of major complications.

Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis

A 72-year-old woman with a sigmoid colon cancer anda synchronous colorectal liver metastasis (CRLM), whichinvolved the right hepatic vein (RHV) and the inferiorvena cava (IVC), was referred to our hospital. Themetastatic lesion was diagnosed as initially unresectablebecause of its invasion into the confluence of theRHV and IVC. After she had undergone laparoscopicsigmoidectomy for the original tumor, she consequentlyhad 3 courses of modified 5-fluorouracil, leucovorin,and oxaliplatin (mFOLFOX6) plus cetuximab. Computedtomography revealed a partial response, and theconfluence of the RHV and IVC got free from cancerinvasion. After 3 additional courses of mFOLFOX6 pluscetuximab, preoperative percutaneous transhepaticportal vein embolization (PTPE) was performed tosecure the future remnant liver volume. Finally, a righthemihepatectomy was performed. The postoperativecourse was uneventful. The patient was dischargedfrom the hospital on postoperative day 13. She hadneither local recurrence nor distant metastasis 18 moafter the last surgical intervention. This multidisciplinarystrategy, consisting of conversion chemotherapy usingFOLFOX plus cetuximab and PTPE, could contributein facilitating curative hepatic resection for initiallyunresectable CRLM.Key words: Initially unresectable; Colorectal liver metastasis;Conversion chemotherapy; Cetuximab; Percutaneoustranshepatic portal vein embolization